Bank of New York Mellon Corp Sells 22,055 Shares of Natera, Inc. (NASDAQ:NTRA)

Bank of New York Mellon Corp lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 2.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 936,629 shares of the medical research company's stock after selling 22,055 shares during the quarter. Bank of New York Mellon Corp owned 0.69% of Natera worth $132,449,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of NTRA. LRI Investments LLC bought a new stake in Natera during the 4th quarter valued at $29,000. Rakuten Securities Inc. increased its stake in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC purchased a new position in Natera during the 1st quarter worth $32,000. EverSource Wealth Advisors LLC boosted its holdings in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the sale, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. The trade was a 34.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,343 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $166.53, for a total value of $889,769.79. Following the sale, the chief executive officer owned 173,728 shares in the company, valued at approximately $28,930,923.84. This represents a 2.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,272 shares of company stock valued at $8,345,368. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NTRA has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. UBS Group lifted their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Piper Sandler lifted their price objective on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Finally, Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Trading Down 1.8%

Shares of NASDAQ:NTRA traded down $2.93 during midday trading on Friday, reaching $160.43. The company had a trading volume of 710,024 shares, compared to its average volume of 1,423,140. The company's 50 day moving average price is $161.05 and its 200 day moving average price is $158.41. The stock has a market cap of $21.91 billion, a P/E ratio of -109.14 and a beta of 1.73. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same period in the previous year, the business posted ($0.56) EPS. The firm's quarterly revenue was up 36.5% compared to the same quarter last year. Research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.